Engineered T-Cell Therapy
Engineered T cells are the result of turning a therapeutic process into a product capable of overcoming checkpoint inhibition, and are the future of adoptive immunotherapy. Cytokine release syndrome,” a storm of molecules generated as the cells fights the cancer. Instead of an antibody, single-chain target domain, he used a human cytokine, IL-13, with a mutation in the sequence that gave high affinity for IL-13 receptor α2. These cells were infused intra cranially, establishing the safety of intracranial administration with some antitumor responses.
- CAR Strategies in Solid Tumours
- Prolongation of T-Cell Response by OX40 CC-Signaling CARS
- Proffered Paper: A New PD-1-CD28 Chimeric Receptor Overcomes PD1-Mediated Immune Suppression in Adoptive T-Cell Therapy
- Proffered Paper: In-Vivo Testing of PSMA-Targeted T-Cell Immunotherapy for Prostate Cancer
Related Conference of Engineered T-Cell Therapy
August 21-22, 2024
5th International conference on Vaccines, Vaccination and Immunization
Paris, France
September 12-13, 2024
19th International Conference on Allergy and Clinical Immunology
Paris, France
October 24-25, 2024
5th International Conference on Immunology And Immunotherapy
Zurich, Switzerland
Engineered T-Cell Therapy Conference Speakers
Recommended Sessions
- Antibody Therapy of Cancer
- Brain Tumors
- Cancer biomarkers
- Cancer clinical trials
- Cancer Immunology & Immunotherapy
- Cancer micro and immuno environment
- Cancer Research
- Cancer vaccines
- Combining Cancer Immunotherapies
- Engineered T-Cell Therapy
- Immune checkpoint inhibitors
- Immuno-Oncology studies
- Immunotherapy - Tumors
- Immunotherapy Monitoring
- Novel Approaches in Cancer & Tumor
- Tumor biology
- Tumor Immunogenicity
- Tumor Immunology
- Tumor immunotherapy research
- Tumor markers and drug targeting
- Tumorigenesis
- Tumors
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)